What's breaking now, across thousands of outlets.
Syndax is ending development of Niktimvo in a rare lung disease called idiopathic pulmonary fibrosis (IPF) after the treatment flunked a mid-stage trial. The company was evaluating Niktimvo in a placebo-controlled Phase 2 study. The ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
The third Qatar International Medical Devices and Healthcare Exhibition and Conference (QMED 2026) will open Wednesday at the Qatar National Convention Center (QNCC), bringing together 55 companies…
From traffic and waiting rooms to doorstep diagnostics, SYNLAB’s home sample collection service is making laboratory testing more convenient, while keeping the focus on quality and accuracy.
Roche is set to fork over up to $100 million in upfront and near-term milestone payments to license an asset in a red-hot field for obesity: ALK7 inhibition.
The Osun State Police Command has organised a mental health awareness lecture for its officers to promote psychological well-being and effective service de Read More…
Der Pharmakonzern sichert mit sich mit der Partnerschaft eine weltweite Lizenz für Wirkstoff gegen Fettleibigkeit. Damit drängt Roche weiter auf den lukrativen Markt für Abnehmpräparate.
Kelly O'Shea says she's "lost faith" in women's health after paying £20k for treatment she needed.
